Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study

Katy shehadeh¹, Yoel Levinsky², rotem tal³, Neta Hana Aviran³, Yonatan Butbul Aviel⁴, Irit Tirosh⁵, Shelly Kagan⁶, Tarek Zoabi³, Shiri Spielman⁷, Adi Miller-Barmak⁴, Rotem Semo Oz⁸, Liora Harel⁹, Gabriel Chodick¹⁰ and Gil Amarilyo⁶, ¹Tel Aviv University, Tel Aviv, Israel, ²Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Rambam Medical center, Haifa, Israel, ⁵Sheba Medical Center, Savyon, Israel, ⁶Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Sheba Tel-HaShomer Medical Center, Givataim, Israel, ⁸Sheba medical center, Herzelyia, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Maccabitech institute for research and innovation, Maccabi healthcare services, Tel Aviv, Israel

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Autoinflammatory Disease, Biologic agents, canakinumab, Colchicine, Familial Mediterranean fever

Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine leads to long-term remission in ~70% of patients. 5% are resistant to colchicine therapy (crFMF) and may be treated with monthly dose of canakinumab (anti IL-1beta). However, colchicine, the only drug proved to prevent secondary amyloidosis. Canakinumab is immunosuppressive as well as expensive. Therefore, we aimed to compare on demand canakinumab (COD) dosage policy vs. canakinumab fixed frequency (CFF) policy.

Methods: Data from 3 Israeli pediatric rheumatology centers (Schneider Children’s Medical Center of Israel, Sheba Tel-HaShomer Medical Center, Rambam Health Care Campus) were collected regarding crFMF patients treated with canakinumab. crFMF patients treated according to the COD policy were given 1 dose of sc-canakinumab injection 4mg/kg (max 150mg), with subsequent doses administered only after an additional attack. CFF patients were given fixed monthly doses according to the manufacturer instructions.

Results: Overall, 51 crFMF (25 COD vs. 26 FCC) with mean follow-up of 22.6 months were included. There were no significant demographic, clinical or genetic differences between the groups. The COD group received significantly lower cumulative canakinumab dosage during the follow-up period (15.688.95mg/kg vs.32.58.05mg/kg; P< 0.001). There were no differences between groups in mean FMF attacks nor in mean CRP levels at the end of follow-up period. None the less, the COD group necessitated higher colchicine doses (0.050.01mg/kg vs. 0.030.01mg/kg; P< 0.001). Overall, 51 crFMF (25 COD vs. 26 FCC) with mean follow-up of 22.6 months were included. There were no significant demographic, clinical or genetic differences between the groups. The COD group received significantly lower cumulative canakinumab dosage during the follow-up period (15.688.95mg/kg vs.32.58.05mg/kg; P< 0.001). There were no differences between groups in mean FMF attacks nor in mean CRP levels at the end of follow-up period. None the less, the COD group necessitated higher colchicine doses (0.050.01mg/kg vs. 0.030.01mg/kg; P< 0.001).

Conclusion: COD treatment in crFMF patients is as effective as CFF treatment. Using COD can reduce drug expenses and decrease immunosuppression exposure without negatively influencing the disease control.

Disclosures: K. shehadeh: None; Y. Levinsky: None; r. tal: None; N. Aviran: None; Y. Butbul Aviel: None; I. Tirosh: None; S. Kagan: None; T. Zoabi: None; S. Spielman: None; A. Miller-Barmak: None; R. Semo Oz: None; L. Harel: None; G. Chodick: None; G. Amarilyo: None.

To cite this abstract in AMA style:

shehadeh K, Levinsky Y, tal r, Aviran N, Butbul Aviel Y, Tirosh I, Kagan S, Zoabi T, Spielman S, Miller-Barmak A, Semo Oz R, Harel L, Chodick G, Amarilyo G. Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/can-children-with-colchicine-resistant-fmf-be-treated-with-on-demand-canakinumab-regimen-a-multicenter-study/. Accessed .

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-children-with-colchicine-resistant-fmf-be-treated-with-on-demand-canakinumab-regimen-a-multicenter-study/